Pressure BioSciences compares to Agilent Technologies, Inc. (NYSE:A), Life Technologies Corporation (NASDAQ:LIFE) and Thermo Fisher Scientific, Inc. (NYSE:TMO) as they are all leading providers of important sample preparation or analytical mass spectrometry equipment, which is widely used in the analysis of small molecules including proteins, DNA and RNA.

While it is rare for the always-reliable and steady life sciences industry to make waves in the press, one company with a long-lasting reputation of nearly a decade has recently forged something of a comeback, receiving headlines the likes of which many younger companies would be envious.  Pressure BioSciences, Inc, (PBIO) currently trading at .22 cents with an average volume of 19,254, has been reporting record numbers throughout the year.  PBIO is a life sciences company which focuses on the development and sale of pressure-based technologies used for analyzing cells and molecules in the fields of forensics, bio-marker discovery, vaccine development, and even counter-bioterror applications.

As demand for these technologies has ballooned over the past several years, Pressure BioSciences has reaped the benefits.  In 2012, total sales for Quarter Three reached a 40% increase over the prior year period, and sales of their proprietary PCT (“Pressure Cycling Technology”) products and services climbed to a 37% increase.  Grant revenue also increased significantly over that same period, while operating losses decreased.

If that isn’t a financially sound business model, we don’t know what is.  And when it comes to financial investments, as anyone skeptical of Pressure BioSciences’ current surge of growth can not only look at the numbers, but also a handful of the Company’s recent accomplishments, to decide whether PBIO is a solid investment.

On November 26th, Pressure BioSciences greatly expanded its product line by entering into a two-way marketing, selling, and distribution agreement with Constant Systems, to offer that company’s “cell disruption equipment and consumables” to consumers all over North America.  On the flip side, Constant Systems will offer PBIO’s PCT technologies in countries throughout Europe – a move that exponentially increases Pressure BioSciences’ exposure and potential revenue, beginning immediately in Q1 2013.

Keen to express his enthusiasm for the deal, Pressure BioSciences, Inc. President and CEO Richard T. Schumacher was quoted as saying: “the two product lines complement each other exceedingly well.  While both the CS and PBI technologies are based on high pressure, each product line has fundamental scientific capabilities that the other does not have.  PBI’s PCT Platform uses certain patented pressure mechanisms to achieve small-scale, molecular level effects.  CS’s technology uses different, proprietary pressure mechanisms for larger-scale, non-molecular level processing.”

This is great news not only for both of these companies, but also for PBIO’s diverse multitude of research-based consumers, which includes Harvard University, the FBI, and agricultural giant Monsanto, as the ability to access these complementary technologies from Pressure BioSciences, without having to negotiate with a third party or import technologies from overseas, will no doubt help make consumer operations run more economically and efficiently.

Pressure BioSciences is undoubtedly a seasoned company with a new agenda.  In addition to their other recent accomplishments, including their distribution deal with Thermos Fisher’s subsidiary Cole Parmer (announced last month), their deal with Constant Systems alone guarantees them a wealth of new opportunities over the course of the next year, beginning immediately. Investors looking for an undervalued stock with the potential for serious short-term gains and long-term stability need look no further than PBIO.


Always read our full disclaimer/disclosure pertaining to this article